(MENAFN- IMARC Group)
The latest research study “Biomarkers market : Global industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032” the global biomarkers market size reached US$ 79.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 220.7 Billion by 2032, exhibiting a growth rate (CAGR) of 11.37% during 2024-2032.
Factors Affecting the Growth of the Biomarkers Industry:
Advancements in Biotechnology and Omics Sciences:
The rapid advancement in biotechnology and omics sciences, such as genomics, proteomics, and metabolomics, has been a significant driver for the growth of the biomarkers market. These technologies have enabled the identification and quantification of numerous biomarkers, enhancing the understanding of various diseases at a molecular level. This scientific progress has led to the development of more precise diagnostic tools, targeted therapies, and personalized medicine approaches. The integration of big data analytics and machine learning in omics research further accelerates biomarker discovery and validation, thus propelling the market growth.
Increasing Prevalence of Chronic Diseases:
The rising prevalence of chronic diseases worldwide, such as cancer, cardiovascular diseases, and neurological disorders, has increased the demand for effective diagnostic and therapeutic solutions. In addition to this, biomarkers play a crucial role in early diagnosis, risk assessment, and monitoring the efficacy of treatments for these diseases. As the global population ages and lifestyle-related health issues increase, the need for biomarker-based tests and personalized healthcare strategies is expected to rise, thereby driving the growth of the biomarkers market.
Growing Investment in Research and Development:
There has been a significant increase in both public and private investment in research and development (R&D) related to biomarkers. This investment is driven by the potential of biomarkers to revolutionize healthcare through early diagnosis, patient stratification, and the development of new, targeted therapies. Pharmaceutical companies, biotech firms, and government agencies are investing heavily in biomarker research to gain a competitive edge in the development of novel diagnostics and therapeutics. This influx of funding accelerates biomarker discovery and facilitates the clinical validation and commercialization of biomarker-based tests.
Request sample brochure:
https://www.imarcgroup.com/biomarkers-market/requestsample
Competitive Landscape with Key Players:
Agilent Technologies Inc. Bio-Rad Laboratories Inc. Charles River Laboratories International Inc. Epigenomics AG Eurofins Scientific SE Merck KGaA Perkinelmer Inc. Qiagen N.V Quanterix Corporation SphingoTec GmbH Thermo Fisher Scientific Inc.
Biomarkers Market Trends:
The growth of the biomarkers market is closely linked to advancements in diagnostic and analytical technologies. Improved imaging modalities, high-throughput screening methods, and sophisticated data analysis tools have enhanced the accuracy, sensitivity, and specificity of biomarker detection. The development of next-generation sequencing (NGS), mass spectrometry, and bioinformatics tools has revolutionized the way biomarkers are identified, measured, and utilized. These technological improvements expand the range of detectable biomarkers but also enable the simultaneous analysis of multiple biomarkers, thus providing a more comprehensive view of disease states and treatment responses.
Browse Full Report With TOC:
https://www.imarcgroup.com/biomarkers-market
Biomarkers Market Report Segmentation:
Breakup by Product:
Consumables Services Software
Consumables represented the largest segment by product in the biomarkers market, primarily due to their recurrent use and essential role in various diagnostic and research applications.
Breakup by Type:
Efficacy Biomarkers Safety Biomarkers Validation Biomarkers
Safety biomarkers emerged as the largest segment by type, reflecting their critical importance in assessing the safety and potential toxicity of new drug candidates during development.
Breakup by Disease:
Cancer Cardiovascular Disorders Neurological Disorders Immunological Disorders Renal Disorders Others
Cancer was the largest segment by disease in the biomarkers market, driven by the high prevalence of cancer globally and the increasing use of biomarkers in cancer diagnosis and personalized treatment.
Breakup by Application:
Diagnostics Drug Discovery and Development Personalized Medicine Others
Drug discovery and development represented the largest segment by application, as biomarkers are extensively utilized in this field for identifying potential drug targets and monitoring drug efficacy and safety.
Breakup by End User:
Pharmaceutical and Biotechnology Companies Diagnostic and Research Laboratories Hospitals and Specialty Clinics Others
Diagnostic and research laboratories formed the largest segment by end user, attributed to their extensive use of biomarkers for disease diagnosis, prognosis, and in conducting various research studies.
Breakup by Region:
North America: (United States, Canada) Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others) Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others) Latin America: (Brazil, Mexico, Others) Middle East and Africa
North America was the largest market by region in the biomarkers field, due to advanced healthcare infrastructure, significant investment in research and development, and the presence of leading pharmaceutical and biotechnology companies.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Contact
US:
IMARC
Group
134
N
4th
St.
Brooklyn,
NY
11249,
USA
Email:
Tel
No:(D)
+91
120
433
0800
United
States:
+1-631-791-1145
|
United
Kingdom:
+44-753-713-2163
MENAFN25022024004122016232ID1107895249
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.